Allergan has agreed to pay up to US$420 M, plus tiered, double-digit royaties, to gain exclusive global rights to Molecular Partners’ retinal disease drug candidate MP0112 for ophthalmic indications. The two companies will collaborate on the protein therapeutic’s Phase IIb development, after which Allergan will be responsible for all development and commercialisation activities.